Thyroid gland undifferentiated (anaplastic) carcinoma

Summary

Thyroid gland undifferentiated (anaplastic) carcinoma (MONDO:0006468) is a cancer with 3 cohort genes (3 CIViC-evidence somatic drivers; 1 ClinVar predisposition record) and 45 clinical trials. Molecularly, BRAF V600E confers sensitivity to Dabrafenib/Trametinib Regimen in Anaplastic Thyroid Carcinoma (CIViC Level A); 7 further subtype–drug associations are mapped below. Top therapeutic interventions include sorafenib, dabrafenib, and carboplatin.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Cohort genes: 3
• ClinVar variants: 1
• Phenotypes (HPO): 23
• Clinical trials: 45
• Precision-medicine evidence (CIViC): 8 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.17	Europe	Validated
Point prevalence	1-9 / 1 000 000	0.1	Europe	Validated

Signs & symptoms

Clinical features (HPO)

23 HPO clinical features (Orphanet curated; top 23 by frequency):

HPO ID	Term	Frequency
HP:0011779	Anaplastic thyroid carcinoma	Obligate (100%)
HP:0000475	Broad neck	Very frequent (80-99%)
HP:0000853	Goiter	Very frequent (80-99%)
HP:0001609	Hoarse voice	Very frequent (80-99%)
HP:0005994	Nodular goiter	Very frequent (80-99%)
HP:0001605	Vocal cord paralysis	Frequent (30-79%)
HP:0002015	Dysphagia	Frequent (30-79%)
HP:0002098	Respiratory distress	Frequent (30-79%)
HP:0002716	Lymphadenopathy	Frequent (30-79%)
HP:0002781	Upper airway obstruction	Frequent (30-79%)
HP:0004894	Laryngotracheal stenosis	Frequent (30-79%)
HP:0012531	Pain	Frequent (30-79%)
HP:0100526	Neoplasm of the lung	Frequent (30-79%)
HP:0001618	Dysphonia	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0002094	Dyspnea	Occasional (5-29%)
HP:0002105	Hemoptysis	Occasional (5-29%)
HP:0010307	Stridor	Occasional (5-29%)
HP:0010622	Neoplasm of the skeletal system	Occasional (5-29%)
HP:0011805	Abnormal skeletal muscle morphology	Occasional (5-29%)
HP:0012735	Cough	Occasional (5-29%)
HP:0002575	Tracheoesophageal fistula	Very rare (<1-4%)
HP:0100836	Malignant neoplasm of the central nervous system	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	thyroid gland undifferentiated (anaplastic) carcinoma
Mondo ID	MONDO:0006468
EFO	EFO:1000595
MeSH	D065646
Orphanet	142
DOID	DOID:0080522
ICD-11	320540024
NCIT	C3878
SNOMED CT	255031003
UMLS	C0238461
MedGen	116064
GARD	0000664
MedDRA	10002240
Anatomy (UBERON)	UBERON:0002046
Is cancer (heuristic)	yes

Also known as: anaplastic carcinoma of the thyroid · anaplastic carcinoma of the thyroid gland · anaplastic carcinoma of thyroid · anaplastic carcinoma of thyroid gland · anaplastic thyroid cancer · anaplastic thyroid carcinoma · anaplastic thyroid gland carcinoma · Dedifferentiated thyroid gland carcinoma · metaplastic thyroid gland carcinoma · pleomorphic thyroid gland carcinoma · sarcomatoid thyroid gland carcinoma · THAP · thyroid cancer, anaplastic · thyroid carcinoma, anaplastic · thyroid gland carcinosarcoma · thyroid gland undifferentiated (anaplastic) carcinoma · thyroid gland undifferentiated carcinoma · undifferentiated (anaplastic) thyroid gland cancer · undifferentiated (anaplastic) thyroid gland carcinoma · undifferentiated carcinoma of the thyroid (+7 more)

Data availability: 1 ClinVar variant · 1 HPO phenotype · 73 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › large cell carcinoma › thyroid gland undifferentiated (anaplastic) carcinoma

Related subtypes (4): lung large cell carcinoma, nasopharyngeal type undifferentiated carcinoma, large cell neuroendocrine carcinoma, salivary gland large cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
12366	NM_000546.6(TP53):c.818G>A (p.Arg273His)	TP53	Pathogenic	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 35 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRAF	Act	BLCA,BRCA,CHOL,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,GBM,GIST,HGGNOS,LGGNOS,LUAD,MEL,MLYM,NSCLC,OVT,PAST,PCM,PRAD,PRCC,PROSTATE,READ,SACA,SKCM,STAD,UCEC,WDTC	CIViC #5
CCND1	Act	HNSC,PCM,UCEC	CIViC #8
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRAF	Orphanet:1340	Cardiofaciocutaneous syndrome
BRAF	Orphanet:146	Differentiated thyroid carcinoma
BRAF	Orphanet:251615	Pilomyxoid astrocytoma
BRAF	Orphanet:389	Langerhans cell histiocytosis
BRAF	Orphanet:500	Noonan syndrome with multiple lentigines
BRAF	Orphanet:54595	Craniopharyngioma
BRAF	Orphanet:58017	Classic hairy cell leukemia
BRAF	Orphanet:626	Large/giant congenital melanocytic nevus
BRAF	Orphanet:648	Noonan syndrome
BRAF	Orphanet:840	Syringocystadenoma papilliferum
BRAF	Orphanet:96253	Cushing disease
CCND1	Orphanet:29073	Multiple myeloma
CCND1	Orphanet:52416	Mantle cell lymphoma
CCND1	Orphanet:67038	B-cell chronic lymphocytic leukemia
CCND1	Orphanet:892	Von Hippel-Lindau disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRAF	HGNC:1097	ENSG00000157764	P15056	Serine/threonine-protein kinase B-raf	civic_evidence
CCND1	HGNC:1582	ENSG00000110092	P24385	G1/S-specific cyclin-D1	civic_evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRAF	Serine/threonine-protein kinase B-raf	Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
CCND1	G1/S-specific cyclin-D1	Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.313
Transcription factor	1	2.8×	0.482
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRAF	Kinase	yes	2.7.10.2	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, PKC_DAG/PE
CCND1	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	1
calcaneal tendon	1
colonic epithelium	1
endometrium epithelium	1
stromal cell of endometrium	1
upper arm skin	1
ganglionic eminence	1
tendon of biceps brachii	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRAF	265	ubiquitous	marker	buccal mucosa cell, colonic epithelium, calcaneal tendon
CCND1	280	ubiquitous	marker	endometrium epithelium, stromal cell of endometrium, upper arm skin
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
CCND1	8,328
BRAF	7,394

Intra-cohort edges

A	B	Sources
BRAF	TP53	string_interaction
CCND1	TP53	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
BRAF	P15056	131
CCND1	P24385	11

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 131. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Transcriptional Regulation by VENTX	2	177.1×	0.005	TP53, CCND1
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	3806.7×	0.009	TP53
Pre-NOTCH Transcription and Translation	2	81.9×	0.009	TP53, CCND1
Interleukin-4 and Interleukin-13 signaling	2	68.6×	0.009	TP53, CCND1
Regulation of TP53 Expression	1	1903.3×	0.014	TP53
Transcriptional activation of cell cycle inhibitor p21	1	951.7×	0.015	TP53
Signaling by MRAS-complex mutants	1	951.7×	0.015	BRAF
Signalling to p38 via RIT and RIN	1	761.3×	0.015	BRAF
Drug-mediated inhibition of CDK4/CDK6 activity	1	761.3×	0.015	CCND1
Activation of NOXA and translocation to mitochondria	1	634.4×	0.015	TP53
Negative feedback regulation of MAPK pathway	1	634.4×	0.015	BRAF
PTK6 Regulates Cell Cycle	1	634.4×	0.015	CCND1
ARMS-mediated activation	1	543.8×	0.015	BRAF
RUNX3 regulates CDKN1A transcription	1	543.8×	0.015	TP53
Prolonged ERK activation events	1	475.8×	0.015	BRAF
SHOC2 M1731 mutant abolishes MRAS complex function	1	475.8×	0.015	BRAF
Gain-of-function MRAS complexes activate RAF signaling	1	475.8×	0.015	BRAF
PI5P Regulates TP53 Acetylation	1	423.0×	0.015	TP53
Activation of PUMA and translocation to mitochondria	1	380.7×	0.015	TP53
Signaling by FGFR3	1	380.7×	0.015	BRAF
RUNX3 regulates WNT signaling	1	380.7×	0.015	CCND1
RUNX3 regulates p14-ARF	1	380.7×	0.015	CCND1
Signaling by FGFR4	1	346.1×	0.015	BRAF
Frs2-mediated activation	1	317.2×	0.015	BRAF
TP53 Regulates Transcription of Caspase Activators and Caspases	1	317.2×	0.015	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	317.2×	0.015	TP53
Urea cycle	1	292.8×	0.015	TP53
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1	292.8×	0.015	CCND1
Signaling by FGFR1	1	271.9×	0.015	BRAF
Regulation of TP53 Activity through Association with Co-factors	1	271.9×	0.015	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
mitotic G1 DNA damage checkpoint signaling	2	702.2×	3e-04	TP53, CCND1
response to X-ray	2	591.3×	3e-04	TP53, CCND1
T cell differentiation in thymus	2	274.0×	0.001	BRAF, TP53
cellular response to xenobiotic stimulus	2	160.5×	0.002	BRAF, TP53
negative regulation of helicase activity	1	5617.3×	0.004	TP53
cellular response to actinomycin D	1	5617.3×	0.004	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	5617.3×	0.004	TP53
negative regulation of G1 to G0 transition	1	5617.3×	0.004	TP53
cellular response to hypoxia	2	80.8×	0.004	TP53, CCND1
negative regulation of neuron apoptotic process	2	73.9×	0.004	BRAF, CCND1
positive regulation of mitochondrial membrane permeability	1	2808.7×	0.005	TP53
oligodendrocyte apoptotic process	1	2808.7×	0.005	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	2808.7×	0.005	TP53
negative regulation of pentose-phosphate shunt	1	2808.7×	0.005	TP53
re-entry into mitotic cell cycle	1	1872.4×	0.005	CCND1
obsolete homolactic fermentation	1	1872.4×	0.005	TP53
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment	1	1872.4×	0.005	BRAF
signal transduction by p53 class mediator	1	1872.4×	0.005	TP53
negative regulation of miRNA processing	1	1872.4×	0.005	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	1872.4×	0.005	TP53
regulation of fibroblast apoptotic process	1	1872.4×	0.005	TP53
T cell proliferation involved in immune response	1	1404.3×	0.005	TP53
positive regulation of programmed necrotic cell death	1	1404.3×	0.005	TP53
response to UV-A	1	1404.3×	0.005	CCND1
oxidative stress-induced premature senescence	1	1404.3×	0.005	TP53
B cell lineage commitment	1	1123.5×	0.005	TP53
T cell lineage commitment	1	1123.5×	0.005	TP53
mRNA transcription	1	1123.5×	0.005	TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly	1	1123.5×	0.005	TP53
positive regulation of axon regeneration	1	1123.5×	0.005	BRAF

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dabrafenib, Pembrolizumab, Trametinib.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 0

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRAF	VEMURAFENIB
CCND1	PALBOCICLIB
TP53	NITROFURANTOIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
BRAF	48	4
CCND1	35	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
VEMURAFENIB	4	BRAF
PONATINIB	4	BRAF
FEDRATINIB	4	BRAF
SORAFENIB	4	BRAF
DASATINIB ANHYDROUS	4	BRAF
RUXOLITINIB	4	BRAF
INFIGRATINIB PHOSPHATE	4	BRAF
INFIGRATINIB	4	BRAF
REGORAFENIB	4	BRAF
DABRAFENIB	4	BRAF
COBIMETINIB	4	BRAF
NILOTINIB	4	BRAF
ABEMACICLIB	4	BRAF, CCND1
ENCORAFENIB	4	BRAF
TOVORAFENIB	4	BRAF
PAZOPANIB	4	BRAF
DASATINIB	4	BRAF
ERLOTINIB	4	BRAF
GEFITINIB	4	BRAF
IMATINIB	4	BRAF
PALBOCICLIB	4	CCND1
RIBOCICLIB	4	CCND1
TRILACICLIB	4	CCND1
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRAF	1,442	Binding:1400, Functional:37, ADMET:5
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
CCND1	576	Binding:574, Functional:1, ADMET:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRAF	2.7.10.2, 2.7.11.1	non-specific protein-tyrosine kinase, non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
BRAF	1,442
CCND1	576
TP53	869

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

25 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	BRAF
FEDRATINIB	4	BRAF
DASATINIB ANHYDROUS	4	BRAF
RUXOLITINIB	4	BRAF
INFIGRATINIB PHOSPHATE	4	BRAF
INFIGRATINIB	4	BRAF
REGORAFENIB	4	BRAF
NILOTINIB	4	BRAF
ENCORAFENIB	4	BRAF
TOVORAFENIB	4	BRAF
PAZOPANIB	4	BRAF
DASATINIB	4	BRAF
ERLOTINIB	4	BRAF
GEFITINIB	4	BRAF
IMATINIB	4	BRAF
PALBOCICLIB	4	CCND1
RIBOCICLIB	4	CCND1
TRILACICLIB	4	CCND1
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	BRAF, CCND1, TP53
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 45.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	21
PHASE1	7
PHASE1/PHASE2	6
Not specified	6
PHASE2/PHASE3	3
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05768178	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT07440290	PHASE2/PHASE3	NOT_YET_RECRUITING	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT00507429	PHASE2/PHASE3	TERMINATED	Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
NCT01701349	PHASE3	WITHDRAWN	Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
NCT04238624	PHASE2	ACTIVE_NOT_RECRUITING	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
NCT05696548	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
NCT06079333	PHASE2	RECRUITING	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
NCT06235216	PHASE2	RECRUITING	Sacituzumab govitEcan in THYroid Cancers
NCT06362694	PHASE2	RECRUITING	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
NCT06374602	PHASE2	RECRUITING	Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
NCT06790706	PHASE2	RECRUITING	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
NCT07470489	PHASE2	NOT_YET_RECRUITING	Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
NCT00095693	PHASE2	TERMINATED	Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
NCT00126568	PHASE2	TERMINATED	Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00603941	PHASE1/PHASE2	TERMINATED	A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
NCT00654238	PHASE2	COMPLETED	Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
NCT01240590	PHASE1/PHASE2	COMPLETED	A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
NCT02152137	PHASE2	COMPLETED	Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT02244463	PHASE1/PHASE2	COMPLETED	A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
NCT02289144	PHASE2	WITHDRAWN	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
NCT02404441	PHASE1/PHASE2	COMPLETED	Phase I/II Study of PDR001 in Patients With Advanced Malignancies
NCT02657369	PHASE2	TERMINATED	A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT02688608	PHASE2	COMPLETED	Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
NCT02726503	PHASE2	COMPLETED	Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
NCT03211117	PHASE2	COMPLETED	Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
NCT03565536	PHASE2	COMPLETED	Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
NCT04400474	PHASE2	COMPLETED	Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
NCT04552769	PHASE2	COMPLETED	Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
NCT04574817	PHASE2	UNKNOWN	Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT04579757	PHASE1/PHASE2	TERMINATED	Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
NCT05102292	PHASE1/PHASE2	UNKNOWN	The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
NCT04420754	PHASE1	ACTIVE_NOT_RECRUITING	Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
NCT06902376	PHASE1	RECRUITING	XL092 and Cemiplimab in BRAF WT Thyroid Cancer
NCT07181720	PHASE1	RECRUITING	CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
NCT07485569	PHASE1	NOT_YET_RECRUITING	Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
NCT00004074	PHASE1	COMPLETED	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT02516774	PHASE1	WITHDRAWN	A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
NCT03122496	PHASE1	COMPLETED	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
NCT03085056	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
NCT05819593	Not specified	NOT_YET_RECRUITING	Evaluating Trends in Anaplastic Thyroid Cancer Patients’ Clinical Study Experiences

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SORAFENIB	4	5
DABRAFENIB	4	4
CARBOPLATIN	4	3
LENVATINIB	4	2
ABEMACICLIB	4	1
CERITINIB	4	1
COBIMETINIB	4	1
FLUDEOXYGLUCOSE F 18	4	1
SACITUZUMAB GOVITECAN	4	1
TRAMETINIB	4	1
VEMURAFENIB	4	1
FOSBRETABULIN	3	2
ZANZALINTINIB	3	2
DOMVANALIMAB	3	1
PUCOTENLIMAB	3	1
SPARTALIZUMAB	3	1
SURUFATINIB	3	1
ZIMBERELIMAB	3	1
EFATUTAZONE	2	3
CROLIBULIN	2	1
EDODEKIN ALFA	2	1
SAPANISERTIB	2	1
CHEMBL5433950	0	2
CHEMBL3415553	0	1
CHEMBL4209555	0	1
CHEMBL4538425	0	1
CHEMBL5190225	0	1
PLX-4720	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 8 predictive associations from 14 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
BRAF V600E	Dabrafenib/Trametinib Regimen	Sensitivity/Response	CIViC A	EID10785 +5
BRAF V600E	Vemurafenib	Sensitivity/Response	CIViC B	EID6045 +1
BRAF V600E	Dabrafenib + Trametinib	Sensitivity/Response	CIViC B	EID6975
ALK Fusion	Crizotinib	Sensitivity/Response	CIViC C	EID5954
BRAF V600	Dabrafenib/Trametinib Regimen	Sensitivity/Response	CIViC C	EID12797
BRAF V600E	Vemurafenib + Radiation Therapy	Sensitivity/Response	CIViC C	EID3743
BRAF V600E	Pertuzumab + Vemurafenib	Sensitivity/Response	CIViC C	EID5961
CCND1 Overexpression	Ribociclib	Sensitivity/Response	CIViC D	EID7790